Miromatrix Medical Inc. is engaged in the development of fully biological human organs for transplant, as well as a family of organ-derived biological mesh products based upon its proprietary perfusion decellularization/recellularization technology, announces the completion for enrollment for its multi-center prospective clinical trial for the evaluation of hernia recurrence requiring reoperation after receiving MIROMESH® implantation. Enrollment for the clinical trial ended with 42 patients spread out over 6 different centers.
MIROMESH® is a novel, non-crosslinked, acellular mesh derived from the highly vascularized porcine liver. By using the whole liver, MIROMESH is able to retain the liver’s native architecture, vasculature and tissue structure. This study will serve to provide clinicians with high-quality data in order to provide them with a higher degree of confidence when selecting MIROMESH® for hiatal hernia repair.